No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn’s Disease Treated with Anti-metabolite Therapy
Picetti D, Kim J, Zhu W, Sandborn W, Jairath V, Singh S. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn’s Disease Treated with Anti-metabolite Therapy. Digestive Diseases And Sciences 2021, 67: 3115-3123. PMID: 34797442, PMCID: PMC9117569, DOI: 10.1007/s10620-021-07301-x.Peer-Reviewed Original ResearchConceptsAnti-metabolite therapyCrohn's diseaseCox proportional hazards analysisCD-related hospitalizationCD-related surgeryAdministrative claims databaseProportional hazards analysisCorticosteroid useTreatment escalationClaims databaseClinical benefitResidual confoundingHigh riskPatientsDisease severityMonotherapyDiseaseKey covariatesTherapyHazard analysisOutcomesRiskEscalationMethodsPatientsHospitalization